<?xml version="1.0" encoding="UTF-8"?>
<p>Integrase inhibitors, including raltegravir, elvitegravir and dolutegravir, are the preferred choice for first-line therapy, based on their improved tolerability, dosing (once daily) and higher barrier to resistance than other antiretroviral drugs (
 <ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/guidelines" xmlns:xlink="http://www.w3.org/1999/xlink">http://aidsinfo.nih.gov/guidelines</ext-link>).
 <xref rid="dkx118-B25" ref-type="bibr">
  <sup>25</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B26" ref-type="bibr">
  <sup>26</sup>
 </xref> Resistance to elvitegravir and raltegravir occurs via several mutational pathways, including: (i) N155H or G140A/G148RHQ pathways conferring raltegravir and elvitegravir cross-resistance; (ii) T66I or E92Q/G elvitegravir-specific pathways; or (iii) the Y143R/H/C raltegravir-specific resistance pathway.
 <xref rid="dkx118-B25" ref-type="bibr">
  <sup>25</sup>
 </xref> Dolutegravir retains antiviral activity against HIV-1 variants resistant to raltegravir and elvitegravir.
 <xref rid="dkx118-B27" ref-type="bibr">
  <sup>27–30</sup>
 </xref> Dolutegravir is far less prone to the development of resistance in first-line therapy with isolated reported cases of the emergence of R263K, N155H or G118R.
 <xref rid="dkx118-B31" ref-type="bibr">
  <sup>31–34</sup>
 </xref> These substitutions have been shown to arise during
 <italic>in vitro</italic> cell culture selection studies.
 <xref rid="dkx118-B27" ref-type="bibr">
  <sup>27</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B35" ref-type="bibr">
  <sup>35</sup>
 </xref> Transmitted resistance to integrase inhibitors remains anecdotal.
 <xref rid="dkx118-B36" ref-type="bibr">
  <sup>36</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B37" ref-type="bibr">
  <sup>37</sup>
 </xref>
</p>
